<SEC-DOCUMENT>0001062993-15-002965.txt : 20150520
<SEC-HEADER>0001062993-15-002965.hdr.sgml : 20150520
<ACCEPTANCE-DATETIME>20150520152839
ACCESSION NUMBER:		0001062993-15-002965
CONFORMED SUBMISSION TYPE:	8-K
PUBLIC DOCUMENT COUNT:		2
CONFORMED PERIOD OF REPORT:	20150520
ITEM INFORMATION:		Regulation FD Disclosure
ITEM INFORMATION:		Financial Statements and Exhibits
FILED AS OF DATE:		20150520
DATE AS OF CHANGE:		20150520

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			LEXARIA CORP.
		CENTRAL INDEX KEY:			0001348362
		STANDARD INDUSTRIAL CLASSIFICATION:	METAL MINING [1000]
		IRS NUMBER:				202000871
		STATE OF INCORPORATION:			NV
		FISCAL YEAR END:			0831

	FILING VALUES:
		FORM TYPE:		8-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	000-52138
		FILM NUMBER:		15879457

	BUSINESS ADDRESS:	
		STREET 1:		SUITE 950, 1130 WEST PENDER STREET
		CITY:			VANCOUVER
		STATE:			A1
		ZIP:			V6E 4A4
		BUSINESS PHONE:		604-602-1675

	MAIL ADDRESS:	
		STREET 1:		SUITE 950, 1130 WEST PENDER STREET
		CITY:			VANCOUVER
		STATE:			A1
		ZIP:			V6E 4A4

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	Lexaria Corp.
		DATE OF NAME CHANGE:	20051229
</SEC-HEADER>
<DOCUMENT>
<TYPE>8-K
<SEQUENCE>1
<FILENAME>form8k.htm
<DESCRIPTION>FORM 8-K
<TEXT>
<HTML>
<HEAD>
   <TITLE>Lexaria Corp.: Form 8-K - Filed by newsfilecorp.com</TITLE>
</HEAD>

<BODY style="font-size:10pt;">

<HR noshade align="center" width=100% size=3 color="black">
<A name=page_1></A>
<P align=center><B><FONT size=5>UNITED STATES </FONT><BR></B><B><FONT
size=5>SECURITIES AND EXCHANGE COMMISSION </FONT><BR>Washington, D.C. 20549
</B></P>
<P align=center><B><FONT size=5>FORM 8-K </FONT></B></P>
<P align=center>Current Report <BR>Pursuant to Section 13 or 15(d) of the
Securities Exchange Act of 1934 </P>
<DIV>
<TABLE
style="BORDER-COLOR: black; FONT-SIZE: 10pt; BORDER-COLLAPSE: collapse; "
borderColor=#000000 cellSpacing=0 cellPadding=3 width="100%" border=1>

  <TR vAlign=top>
    <TD align=left colSpan=3>Date of Report (date of earliest event reported):
      May 20, 2015 <BR></TD>
    </TR>
  <TR vAlign=bottom>
    <TD align=center colSpan=3><B><FONT size=5><U>LEXARIA CORP.
      </U></FONT></B><BR>(Exact name of registrant as specified in its charter) <BR></TD></TR>
  <TR vAlign=top>
    <TD align=center><U><B>Nevada </B></U><BR>(State or other
      jurisdiction of <BR>incorporation) </TD>
    <TD align=center width="33%"><U><B>000-52138
      </B></U><BR>(Commission File Number) <BR></TD>
    <TD align=center width="33%"><U><B>20-2000871 </B></U><BR>(IRS
      Employer Identification No.) <BR></TD></TR>
  <TR vAlign=top>
    <TD align=left colSpan=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<B>#950 &#150; 1130 West
      Pender Street, Vancouver, British Columbia, Canada V6E 4A4 </B></TD>
    <TD align=left width="33%">&nbsp; </TD></TR>
  <TR vAlign=top>
    <TD align=left colSpan=3>Registrant's telephone number, including area
      code: <B><U>(604) 602-1675 </U></B></TD></TR>
  <TR vAlign=bottom>
    <TD align=center colSpan=3>(Former name or former address, if changed
      since last report.) </TD></TR></TABLE></DIV>
<P align=justify>Check the appropriate box below if the Form 8-K filing is
intended to simultaneously satisfy the filing obligation of the registrant under
any of the following provisions: </P>
<P align=justify>[&nbsp; ]&nbsp; Written communications pursuant to Rule 425
under the Securities Act (17 CFR 230.425) </P>
<P align=justify>[&nbsp; ]&nbsp; Soliciting material pursuant to Rule 14a-12
under the Exchange Act (17 CFR 240.14a -12) </P>
<P align=justify>[&nbsp; ]&nbsp; Pre-commencement communications pursuant to
Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d -2(b)) </P>
<P align=justify>[&nbsp; ]&nbsp; Pre-commencement communications pursuant to
Rule 13e-4(c) under Exchange Act (17 CFR 240.13e -4(c)) </P>
<HR style="PAGE-BREAK-AFTER: always" align=center width="100%" color=black
noShade SIZE=5>
<!--$$/page=--><A name=page_2></A><BR>
<TABLE
style="BORDER-COLOR: black; FONT-SIZE: 10pt; BORDER-COLLAPSE: collapse; "
cellSpacing=0 cellPadding=0 width="100%" border=0>

  <TR vAlign=top>
    <TD align=left><B>Item 7.01&nbsp; Regulation FD Disclosure.</B>
  </TD></TR></TABLE>
<P align=justify>A copy of the news release announcing bioavailability testing
to commence on patent-pending technology update filed as exhibit 99.1 to this
current report and is hereby incorporated by reference. </P>
<P align=justify><B>TEM 9.01.&nbsp; FINANCIAL STATEMENTS AND EXHIBITS. </B></P>
<TABLE
style="BORDER-COLOR: black; FONT-SIZE: 10pt; BORDER-COLLAPSE: collapse; "
cellSpacing=0 cellPadding=0 width="100%" border=0>

  <TR vAlign=top>
    <TD noWrap align=justify><B>Exhibit No.</B> </TD>
    <TD noWrap align=justify width="90%"><B>Description</B> </TD></TR>
  <TR>
    <TD noWrap align=justify >&nbsp;</TD>
    <TD noWrap align=justify width="90%" >&nbsp;</TD></TR>
  <TR vAlign=top>
    <TD align=justify bgColor=#eeeeee><a href="exhibit99-1.htm">99.1</a> </TD>
    <TD align=justify width="90%" bgColor=#eeeeee><a href="exhibit99-1.htm">News Release dated May 20,
      2015</a> </TD></TR></TABLE><BR>
<HR style="PAGE-BREAK-AFTER: always" align=center width="100%" color=black
noShade SIZE=5>
<A name=page_3></A>
<P align=center><B>SIGNATURES </B></P>
<P align=justify>Pursuant to the requirements of the Securities Exchange Act of
1934, the Registrant has duly caused this report to be signed on its behalf by
the undersigned hereunto duly authorized. </P>
<TABLE
style="BORDER-COLOR: black; FONT-SIZE: 10pt; BORDER-COLLAPSE: collapse; "
cellSpacing=0 cellPadding=0 width="100%" border=0>

  <TR vAlign=top>
    <TD align=left colSpan=2>Dated: May 20, 2015 </TD>
    <TD align=left width="88%">&nbsp; </TD></TR>
  <TR>
    <TD>&nbsp; </TD>
    <TD width="4%">&nbsp; </TD>
    <TD width="88%">&nbsp; </TD></TR>
  <TR vAlign=top>
    <TD align=left>&nbsp; </TD>
    <TD align=left width="92%" colSpan=2>Lexaria Corp. </TD></TR>
  <TR vAlign=top>
    <TD align=left>&nbsp;(Signature) </TD>
    <TD align=left
      width="4%"><U>By:&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
      </U></TD>
    <TD align=right width="88%">
      <P align=justify><U>&#147;<I>/s/ Chris
      Bunka&#148;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</I></U>&nbsp;</P></TD></TR>
  <TR vAlign=top>
    <TD align=left>&nbsp; </TD>
    <TD align=left width="92%" colSpan=2>Chris Bunka </TD></TR>
  <TR vAlign=top>
    <TD align=left>&nbsp; </TD>
    <TD align=left width="92%" colSpan=2>President &amp; CEO
</TD></TR></TABLE><BR>
<HR align=center width="100%" color=black noShade SIZE=5>

</BODY>

</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.1
<SEQUENCE>2
<FILENAME>exhibit99-1.htm
<DESCRIPTION>EXHIBIT 99.1
<TEXT>
<HTML>
<HEAD>
   <TITLE>Lexaria Corp.: Exhibit 99.1 - Filed by newsfilecorp.com</TITLE>
</HEAD>

<BODY style="font-size:10pt;">

<HR noshade align="center" width=100% size=3 color="black">
<!--$$/page=--><A name=page_1></A>
<P align=center><B>Bioavailability Testing to Commence On Lexaria&#146;s
Patent-Pending Technology </B></P>
<P align=justify>Kelowna, BC / May 20, 2015 / Lexaria, Corp. (OTCQB:LXRP)
(CSE:LXX) (the &#147;Company&#148;) is pleased to announce it has engaged Absorption
Systems LP in the USA, to begin third party <I>in vitro</I> tests using a human
intestinal tissue model to evaluate the cannabidiol (CBD) permeability of its
patent-pending technology that infuses cannabinoid compounds within lipids. </P>
<P align=justify>The study will assess CBD permeability achieved with our
proprietary ViPova&#153; tea formulation at multiple sampling time points compared to
positive and negative controls under strict experimental conditions. <I>In
vitro</I> testing using human tissue models can be preferable to animal testing
since human cells can be used directly to provide species-specific permeability
results.</P>
<P align=justify>&#147;Although we cannot know in advance the outcome of such tests,
the results have the potential to materially affect future outcomes for the
Company&#148;, said John Docherty, president of Lexaria. &#147;We have a wealth of
anecdotal evidence from our growing ViPova&#153; customer base extolling the marked
effects of our CBD-infused tea and we look forward to the outcome of this study
to help quantify this in detail.&#148; </P>
<P align=justify>It is generally accepted in pharmacological sectors that the
bioavailability of any active ingredient is one of the most important factors
determining its effects on the body. Enhanced bioavailability can be extremely
useful and is highly valued for any useful molecule, including CBD and
tetrahydrocannabinol (THC). </P>
<P align=justify>Lexaria expects to begin this testing in the near future and
will report results when they are available in due course, expected within the
next 3-4 months. </P>
<P align=justify>About Lexaria <BR>Lexaria is a food sciences company focused on
the delivery of cannabinoid compounds procured from legal, agricultural hemp,
through gourmet foods based upon its proprietary infusion technologies.
www.lexariaenergy.com </P>
<P align=justify>About ViPova<SUP>TM</SUP> <BR>ViPova<SUP>TM</SUP> uses only
legal CBD oil extracts, grown from agricultural hemp in locations where it is
legal to do so, in ViPova<SUP>TM</SUP>-branded tea. ViPova<SUP>TM</SUP> uses its
patent-pending process to infuse concentrated amounts of CBD within lipids in
its tea, providing more bioactivity and comfort to the body during the
absorption process. Only ViPova<SUP>TM</SUP> has this ground-breaking technology
for CBD/lipid infusion. <U>www.vipova.com</U> </P>
<HR style="PAGE-BREAK-AFTER: always" align=center width="100%" color=black
noShade SIZE=5>
<!--$$/page=--><A name=page_2></A>
<P align=justify>About Absorption Systems <BR>Absorption Systems assists
pharmaceutical, biotechnology and medical device companies in identifying and
overcoming ADMET (Absorption, Distribution, Metabolism, Excretion and Toxicity)
barriers in the development of drugs, biologics and medical devices. The
company's mission is to continually develop innovative research tools that can
be used to accurately predict human outcomes or to explain unanticipated human
outcomes when they occur. Absorption Systems, with facilities near Philadelphia,
PA, in San Diego, CA, and in Panama, serves customers throughout the world. For
information on the company's comprehensive contract services and applied
research programs, please visit www.absorption.com. </P>
<P align=justify>FOR FURTHER INFORMATION PLEASE CONTACT:</P>
<P align=justify>Lexaria Corp. <BR>Chris Bunka <BR>Chairman &amp; CEO <BR>(250)
765-6424 </P>
<P align=justify>FORWARD-LOOKING STATEMENTS </P>
<P align=justify>This release includes forward-looking statements. Statements
which are not historical facts are forward-looking statements. The Company makes
forward-looking public statements concerning its expected future financial
position, results of operations, cash flows, financing plans, business strategy,
products and services, competitive positions, growth opportunities, plans and
objectives of management for future operations, including statements that
include words such as "anticipate," "if," "believe," "plan," "estimate,"
"expect," "intend," "may," "could," "should," "will," and other similar
expressions are forward-looking statements. Such forward-looking statements are
estimates reflecting the Company's best judgment based upon current information
and involve a number of risks and uncertainties, and there can be no assurance
that other factors will not affect the accuracy of such forward-looking
statements. Access to capital, or lack thereof, is a major risk and there is no
assurance that the Company will be able to raise required working capital.
Factors which could cause actual results to differ materially from those
estimated by the Company include, but are not limited to, government regulation,
managing and maintaining growth, the effect of adverse publicity, litigation,
competition and other factors which may be identified from time to time in the
Company's public announcements and filings. There is no assurance that the
medical marijuana, CBD sector, or alternative health businesses will provide any
benefit to Lexaria, or that the Company will experience any growth through
participation in these sectors. There is no assurance that any planned corporate
activity, business venture, or initiative will be pursued, or if pursued, will
be successful. There is no assurance that any cannabinoid-based product will
promote, assist, or maintain any beneficial human health conditions whatsoever.
There is no assurance that the cannabinoid/lipid infusion technology will
provide any increase in bioavailability to any individual person, nor that
bioavailability testing will produce any positive result. No statement herein
has been evaluated by the Food and Drug Administration (FDA).
ViPova<SUP>TM</SUP> products are not intended to diagnose, treat, cure or
prevent any disease. </P>

<P align=justify><I>The CSE has not reviewed and does not accept responsibility
for the adequacy or accuracy of this release. </I></P>
<HR align=center width="100%" color=black noShade SIZE=5>

</BODY>

</HTML>
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
